Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewRECTAS (rectifier of aberrant splicing) is a pre-mRNA splicing modulator of the IKBKAP (inhibitor of κ light polypeptide gene enhancer in B-cells, kinase complex associated protein) gene. It corrects aberrant IKBKAP splicing in vitro in cellular models of familial dysautonomia and in vivo in transgenic mice. In combination with Phenylbutyric acid (Cat. No. 2682), RECTAS rescues PARK7 aberrant splicing and neuronal cell loss in a midbrain organoid model of familial Parkinson's disease. Orally bioavailable and brain penetrant.
M. Wt | 249.66 |
Formula | C10H8ClN5O |
Storage | Store at -20°C |
Purity | ≥98% (HPLC) |
CAS Number | 101862-47-9 |
PubChem ID | 5037694 |
InChI Key | QGUOPVCOXHVPJX-UHFFFAOYSA-N |
Smiles | ClC1=NC=2N=CNC2C(=N1)NCC=3OC=CC3 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 24.97 | 100 |
The following data is based on the product molecular weight 249.66. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 4.01 mL | 20.03 mL | 40.05 mL |
5 mM | 0.8 mL | 4.01 mL | 8.01 mL |
10 mM | 0.4 mL | 2 mL | 4.01 mL |
50 mM | 0.08 mL | 0.4 mL | 0.8 mL |
References are publications that support the biological activity of the product.
Ajiro et al (2021) Therapeutic manipulation of IKBKAP mis-splicing with a small molecule to cure familial dysautonomia. Nat.Commun. 12 4507 PMID: 34301951
Yoshida et al (2015) Rectifier of aberrant mRNA splicing recovers tRNA modification in familial dysautonomia. Proc.Natl.Acad.Sci U.S.A. 112 2764 PMID: 25675486
Boussaad et al (2020) A patient-based model of RNA mis-splicing uncovers treatment targets in Parkinson's disease. Sci.Transl.Med. 12 eaau3960 PMID: 32908004
If you know of a relevant reference for RECTAS, please let us know.
Keywords: RECTAS, RECTAS supplier, IKBKAP, splicing, modulator, modulates, familial, dysautonomia, FD, brain, penetrant, orally, bioavailable, PARK7, DJ-1, parkinsons, disease, DNA,, RNA, and, Protein, Synthesis, Polymerase, 7679, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for RECTAS. Do you know of a great paper that uses RECTAS from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review RECTAS and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This product guide provides a review of the cell cycle and DNA damage research area and lists over 150 products, including research tools for:
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of: